Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be releasing its earnings data after the market closes on Tuesday, November 7th. Analysts expect Bellicum Pharmaceuticals to post earnings of ($0.73) per share for the quarter.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period last year, the company earned ($0.61) EPS. On average, analysts expect Bellicum Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Bellicum Pharmaceuticals, Inc. (BLCM) opened at $10.12 on Friday. The company has a quick ratio of 8.34, a current ratio of 8.34 and a debt-to-equity ratio of 0.22.

BLCM has been the subject of a number of recent research reports. Zacks Investment Research raised Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Raymond James Financial, Inc. set a $18.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. BidaskClub lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Bellicum Pharmaceuticals in a report on Thursday, August 10th. Finally, ValuEngine lowered Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, August 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $26.20.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.